Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Short term Debt: 2024-2025

Historic Short term Debt for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $4.3 million.

  • Kura Oncology's Short term Debt rose 152.89% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 152.89%. This contributed to the annual value of $2.6 million for FY2024, which is N/A change from last year.
  • Per Kura Oncology's latest filing, its Short term Debt stood at $4.3 million for Q3 2025, which was up 39.36% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Short term Debt peaked at $4.3 million during Q3 2025, and registered a low of $847,000 during Q2 2024.
  • Over the past 2 years, Kura Oncology's median Short term Debt value was $2.3 million (recorded in 2024), while the average stood at $2.4 million.
  • Data for Kura Oncology's Short term Debt shows a peak YoY surged of 267.41% (in 2025) over the last 5 years.
  • Over the past 2 years, Kura Oncology's Short term Debt (Quarterly) stood at $2.6 million in 2024, then spiked by 152.89% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $3.1 million for Q2 2025, and $1.9 million during Q1 2025.